Cart
sales@molnova.com
IDH1-IN-1
CAS No. 1355326-21-4
IDH1-IN-1( Mutant IDH1-IN-1 )
Catalog No. M11452 CAS No. 1355326-21-4
Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 84 | In Stock |
|
| 5MG | 140 | In Stock |
|
| 10MG | 215 | In Stock |
|
| 25MG | 412 | In Stock |
|
| 50MG | 606 | In Stock |
|
| 100MG | 862 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIDH1-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionMutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).
-
DescriptionMutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent); more bioactivity information in Patent WO2012009678A1(Example 135).
-
In Vitro——
-
In Vivo——
-
SynonymsMutant IDH1-IN-1
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
Recptormutant IDH1 R132H
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1355326-21-4
-
Formula Weight498.59
-
Molecular FormulaC30H31FN4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESO=C(NC1CCCCC1)C(N(C(CN2C3=CC=CC=C3N=C2)=O)C4=CC=CC(F)=C4)C5=CC=CC=C5C
-
Chemical Name2-(N-[2-(Benzimidazol-1-yl)acetyl]-3-fluoroanilino)-N-cyclohexyl-2-(2-methylphenyl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Janeta Popovici-Muller, et al. Patent WO2012009678 A
molnova catalog
related products
-
PfDHODH-IN-1
PfDHODH-IN-1 is an inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase(PfDHODH) which catalyzes the rate-limiting step for DNA and RNA biosynthesis. PfDHODH-IN-1 has antimalarial activity.
-
DHODH-IN-23
DHODH-IN-23 is a DHODH inhibitor with oral activity. DHODH-IN-23 is often used in cancer research.
-
Carbenoxolone
Carbenoxolone is an inhibitor of 11β-HSD and gap junction connexin channels. Carbenoxolone inhibits macrophage migration into atria and prevents the development of fatty liver disease.
